

CTMB Meeting March 13, 2019

The Charitable Trust Management Board (CTMB) of the Newfoundland Club of America Charitable Trust met via teleconference on March 13, 2019. Clyde E. Dunphy called the meeting to order at 7:35 p.m. CST. Members present were Clyde Dunphy, John Cornell, Mary Lou Cuddy, Denise Hatakeyama, Lori Littleford, Chris Plum, Roger Powell, Mary L. Price, and Mary Jane Spackman. Lori moved to approve the minutes of February 6, 2019 as corrected. Mary Lou seconded. Motion passed unanimously.

Chairman's Report: Clyde reported the Charitable Trust Annual Report is at the printer's for distribution with the First Quart *Newf Tide*.

Clyde reported he is registered for the AKC Parent Club Health Conference as the representative of the Trust, John Cornell is the representative from the NCA. In addition, the final policy copy of the Forelimb Anomaly Group (NFLAC) will be distributed at the April meeting for discussion/approval.

Secretary's Report: none

Treasurer's Report: Mary L. Price reported the Trust's cash balances as of March 10, 2019: Newfoundland Health Challenge (NHC): checking account—\$20,779.29; SAS Research Fundraising- \$4,168.00; invested in CDs—\$ 20,000.00; Money Market Account--\$25,280.78; MS Brokerage Account-- \$83,031.63 Health Challenge total—\$ 153,259.70, Rescue Fund checking account—\$16,740.44; Barrister Fund-\$ 3,725.00; Money Market Account-\$30,334.26; MS Brokerage Account- \$299,039.97; Rescue total—\$349,839.67. Scholarship Checking- \$1,468.26 ; MM Account- \$10,213.23 ; Scholarship Total- \$ 11,681.49; Endowment Fund: Morgan Stanley unrestricted: \$33,086.16; Education Fund- MM Acct.-\$4,490.18 ; Endowment Fund Unrestricted - MM Acct.- \$1,252.59; Trust Management Checking - \$3,890.20; MM Acct.- \$3,034.59.; Trust Management Total- \$6,924.79 Total Charitable Trust—\$ 560,534.58.

(Newfoundland Health Challenge adjustments; Newfoundland Health Challenge — \$70,228.07; AKC Canine Health Foundation Donor Advised Fund as of 9/30/2018 \$17,912.01; \$0 reserved for Grants for total NHC balance of \$88,140.08).

(Scholarship adjustments; Reserve for scholarships - \$10,091.90; Funds available - \$1,589.59)

In addition Mary reported the year end appeal raised \$3050.00 from 28 donors. In addition funds from the sale of donated memorabilia offered online have raised \$861.00 as of November 1.

Rescue: Mary reported #? Newfoundlands were surrendered from a North Dakota producer into NCA Rescue and the Minnesota Newfoundland Rescue which is an independent Rescue. The Minnesota Rescue had the resources to take this group in for NCA Rescue.

Following discussion, the \$1,000.00 grant approved by email for Ruby from the Bannister Fund, was by consensus ratified.

Mary presented a request from Rescue to take orders for Rescue softgoods at the National, by consensus it was approved.

Old Business: Clyde will contact Morris Animal Foundation to see if a scientific officer from Morris would be available to call into a CT meeting to discuss the question on SAS research possibilities.

New Business: It was brought to attention of the Trust that various companies post items for sale on the Trust website as well as the NCA National Specialty website with a commitment to donate an unknown percentage to the Trust based upon sales. In response, an ad hoc committee was formed to establish a policy for any future items. The Committee will be chaired by Chris Plum, along with Mary L and Roger. Input/advice will be sought from Marylou Zimmerman. Until a policy is approved, there will be a moratorium on such postings. Clyde will inform Marylou Zimmerman of this action.

Mary Jane moved to fund the below listed studies at Morris Animal Foundation at a cost of \$10,000.00 per grant. (\$10,000.00 is the minimum to be a co-sponsor and receive all related reports to the study) Lori seconded, Motion passed unanimously:

D18CA-050**Mechanism of Action of a Novel, Safe and Effective Ligand Targeted Therapy to Define the Repertoire of Tumor Targets****Dr. Jaime F. Modiano, VMD, PhD University of Minnesota****Study Start Date: 12/1/2017 Projected End Date: 12/1/2019 Grant Amount: \$182,807.00**

SUMMARY: Researchers will determine if a promising new drug used to treat dogs with hemangiosarcoma would benefit dogs with other incurable cancers.

DESCRIPTION: Researchers recently developed a new cancer drug, eBAT, which improved post-diagnostic survival of dogs with a particularly deadly type of cancer called hemangiosarcoma. There has been virtually no gains in treatment for this disease since the introduction of surgery and adjunct chemotherapy in the 1980s, and this new drug is a promising step forward. eBAT uses proteins that fuel the growth of cancer cells as “baits” to deliver a lethal drug payload with high specificity to its target. eBAT is unique because it is designed to target cancer cells and the environment cancer cells take over. In this project, the researchers will define specifically how eBAT works to make the body inhospitable to cancer cells and determine the drug’s potential to improve overall survival of dogs with other incurable cancers.

D19CA-083**Interrogating the regulation, function and therapeutic potential of monocarboxylate transporters in osteosarcoma****Dr. Cheryl A. London, DVM, PhD Tufts University****Study Start Date: 10/1/2018 Projected End Date: 10/1/2020 Grant Amount: \$97,377.00**

SUMMARY: Researchers will study metabolic irregularities associated with osteosarcoma that may contribute to disease progression, chemotherapy resistance and cancer spread.

DESCRIPTION: Cancer cells have high energy needs and take advantage of the available nutrients and oxygen in their environment to help maintain their high metabolic rate by using glucose (sugar) for energy, a process which generates lactic acid. Too much lactic acid can be harmful to cells. However, cancer cells have developed strategies to avoid toxicity from lactic acid by increasing expression of two proteins, MCT1 and MCT4, that move lactate in and out of the cell. This strategy allows cancer cells to maintain their accelerated growth rates despite high lactic acid concentration. Researchers will investigate how canine

cancer cells regulate MCT1 and MCT4 as their metabolic needs change. Findings will not only advance our understanding of the biology of cancer cell metabolism but provide information on the feasibility of blocking this pathway as a way of treating this devastating cancer.

D19CA-035

A new and relevant target for dog joint pain: Neurotrophic factor receptor GFR α 3 and its ligand, artemin, are master regulators of osteoarthritis pain in the dog

Dr. B. Duncan X. Lascelles, BVSc, PhD, MRCVS North Carolina State University

Study Start Date:11/1/2018 Projected End Date:11/1/2019 Grant Amount: \$48,568.00

SUMMARY: Researchers will learn more about what drives pain in dogs with osteoarthritis and use this new information to help identify safer pain relief options for affected animals.

DESCRIPTION: In the United States, 20 percent to 40 percent of dogs are affected by osteoarthritis-related (OA) pain. This condition also is a leading cause of euthanasia in dogs. The only approved drugs for treatment frequently fall short in managing pain and some have devastating side effects. Researchers will study tissue samples from affected dogs to learn more about the mechanisms responsible for OA pain. A better understanding of the pain process will provide a foundation for future studies on how to turn off or suppress these mechanisms, opening the door for the discovery of novel, effective and safe pain relief options for dogs with OA pain.

A subscription inquiry was received from the University of Pennsylvania concerning our continued participation in the C-BARQ study. This is an ongoing Behavioral Study which the CT has sponsored in the past for Newfoundlanders. There was not adequate information to act on, so Clyde will try to individual responsible for the study.

The CT will send a representative to the Annual Morris Animal Foundation Meeting in Denver. Chris and Denise will check their schedules to see if either is available. Clyde will be the back-up to attend,.

It was the consensus that a new Health Survey will be released in January of 2020.

The next meeting of the CTMB will be Wednesday, April 3, 2019 at 7:30 CST.

Lori moved to adjourn at 9:00 CDT. Roger seconded. Motion passed unanimously.